Novartis Reports Positive Ultibro Phase III Study Results For COPD

Novartis announced positive first results from the Phase III head to head LANTERN study. The study was comparing how once-daily Ultibro Breezhaler (indacaterol/glycopyrronium) improved lung function compared to twice-daily Seretide Accuhaler (salmeterol/fluticasone (SFC)) in patients with chronic obstruction pulmonary disease (COPD) with or without a history of moderate to severe exacerbations in the previous year. The trial met its primary and secondary endpoints, demonstrating Ultibro Breezhaler’s superiority over Seretide.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news